Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.74 |
| ▸ | SRD5A1 | P18405 | 4/20 | 0.66 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | INPP5D | Q92835 | 1/20 | 0.64 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.61 |
| ▸ | SHBG | P04278 | 1/20 | 0.61 |
| ▸ | PGR | P06401 | 1/20 | 0.61 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.61 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | AR | P10275 | 1/20 | 0.61 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | MGAM | O43451 | 1/20 | 0.61 |
| ▸ | USP2 | O75604 | 2/20 | 0.59 |
| ▸ | CDC25A | P30304 | 2/20 | 0.58 |
| ▸ | POLA1 | P09884 | 1/20 | 0.58 |
| ▸ | FGF2 | P09038 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cholestan-3-One SCHEMBL31415973 | 1.00 | GPBAR1 (0.74) | GPBAR1SRD5A1SRD5A2CYP2D6CYP2C19 | |
| Cholestan-3-One SCHEMBL14078297 | 1.00 | GPBAR1 (0.74) | GPBAR1SRD5A1SRD5A2CYP2D6CYP2C19 | |
| Cholestan-3-One SCHEMBL17817037 | 1.00 | GPBAR1 (0.74) | GPBAR1SRD5A1SRD5A2CYP2D6CYP2C19 | |
| Cholestan-3-One SCHEMBL17817346 | 1.00 | GPBAR1 (0.74) | GPBAR1SRD5A1SRD5A2CYP2D6CYP2C19 | |
| Cholestan-3-One SCHEMBL14313461 | 1.00 | GPBAR1 (0.74) | GPBAR1SRD5A1SRD5A2CYP2D6CYP2C19 | |
| Cholestan-3-One SCHEMBL24151938 | 1.00 | GPBAR1 (0.74) | GPBAR1SRD5A1SRD5A2CYP2D6CYP2C19 | |
| Cholestan-3-One SCHEMBL14360529 | 1.00 | GPBAR1 (0.74) | GPBAR1SRD5A1SRD5A2CYP2D6CYP2C19 | |
| Cholestan-3-One SCHEMBL12273856 | 1.00 | GPBAR1 (0.74) | GPBAR1SRD5A1SRD5A2CYP2D6CYP2C19 | |
| Cholestan-3-One SCHEMBL643015 | 1.00 | GPBAR1 (0.74) | GPBAR1SRD5A1SRD5A2CYP2D6CYP2C19 | |
| Cholestan-3-One SCHEMBL30428888 | 1.00 | GPBAR1 (0.74) | GPBAR1SRD5A1SRD5A2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060228388-A1 | Method for controlling an insect species using a synthetic trail pheromone mimic | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 2006-10-12 | — | — | US | claimed |
| US-20060217358-A1 | Use of derivatives of cholest-4-en-3-one as medicaments, pharmaceutical compositions containing same, novel derivatives and preparation method thereof | TROPHOS (FR) | 2006-09-28 | — | — | US | claimed |
| EP-1601363-A2 | USE OF DERIVATIVES OF CHOLEST-4-EN-3-ONE AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, NOVEL DERIVATIVES AND PREPARATION METHOD THEREOF | Trophos (FR) | 2005-12-07 | — | — | EP | claimed |
| WO-2004082581-A2 | USE OF DERIVATIVES OF CHOLEST-4-EN-3-ONE AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, NOVEL DERIVATIVES AND PREPARATION METHOD THEREOF | TROPHOS (FR) | 2004-09-30 | — | — | WO | claimed |
| EP-0754457-B1 | ANTIOBESTIC AGENT | RIKEN (JP) | 2003-01-02 | — | — | EP | claimed |
| US-6312919-B1 | CONVERTING CHOLESTEROL TO 4-CHOLESTEN-3-ONE, THEN TO COPROSTAN-3-ONE, AND THEN TO COPROSTANOL BY VARIOUS DEHYDROGENASES ISOLATED FROM A EUBACTERIUM SPECIES; FOR REDUCED CHOLESTEROL FOODS AND FEEDS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-11-06 | — | — | US | claimed |
| US-20010034041-A1 | Process for producing a cholesterol-reduced substance | SAITOH CHIAKI (JP) | 2001-10-25 | — | — | US | claimed |
| US-20010005587-A1 | Cholesterol dehydrogenase, coprostan-3-one dehydrogenase and 4-cholesten-3-one dehydrogenase, compositions containing the dehydrogenases, and method for reducing amount of cholesterol using the compositions | SAITOH CHIAKI (JP) | 2001-06-28 | — | — | US | claimed |
| US-5846962-A | Anti-obesity agents | THE INSTITUTE OF PHYSICAL AND CHEMICAL RESEARCH (JP) | 1998-12-08 | — | — | US | claimed |
| EP-0879892-A1 | PROCESS FOR PREPARING CHOLESTEROL-LOWERING COMPOUND | Kyowa Hakko Co., Ltd. (JP) | 1998-11-25 | — | — | EP | claimed |
| US-5710143-A | 3-KETOSTEROIDS | INSTITUTE OF PHYSICAL AND CHEMICAL RESEARCH (JP) | 1998-01-20 | — | — | US | claimed |
| EP-0754457-A1 | ANTIOBESTIC AGENT | THE INSTITUTE OF PHYSICAL & CHEMICAL RESEARCH (JP) | 1997-01-22 | — | — | EP | claimed |
| JP-7165587-A | — | — | None | — | — | JP | disclosed |
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| WO-2025096734-A1 | MICROCAPSULES | FMC CORPORATION (US) | 2025-05-08 | — | — | WO | disclosed |
| EP-4522646-A2 | APOE LIPOPROTEIN SYSTEMS | Kisbee Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-0754457-A1 | ANTIOBESTIC AGENT | THE INSTITUTE OF PHYSICAL & CHEMICAL RESEARCH (JP) | 1997-01-22 | — | — | EP | disclosed |
| JP-H07165587-A | ANTIOBESTIC MEDICINE | RIKAGAKU KENKYUSHO | 1995-06-27 | — | — | JP | disclosed |
| WO-1995002424-A1 | LOCALIZATION AND THERAPY OF NON-PROSTATIC ENDOCRINE CANCER WITH AGENTS DIRECTED AGAINST PROSTATE SPECIFIC ANTIGEN | NORDION INTERNATIONAL INC. (CA) | 1995-01-26 | — | — | WO | disclosed |
| US-5334712-A | Estrane or androstane pyridinyl alkyl or alkylphenyl amine steroids for antidiabetes and obesity | THE UPJOHN COMPANY (US) | 1994-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | APOB, APOL1, LDLR | GPBAR1 1121/4885SRD5A1 3822/4885SRD5A2 3465/4885 |
| US-20060217358-A1 | Use of derivatives of cholest-4-en-3-one as medicaments, pharmaceutical compositions containing same, novel derivatives and preparation method thereof | CYP46A1, NR1H4, CYP27A1 | GPBAR1 22/4885SRD5A1 34/4885SRD5A2 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.